what makes us unique

At Complete Phase CRO, we collaborate closely with your team, providing expertise to optimise your time and budget allocation.

Our Advantage

With 50+ years of combined expertise, our skilled team has successfully guided investigational products from development to market.

See Our Solutions

Quality Service

Our team comprises experienced industry leaders, each averaging 20 years of experience and has a track record of successfully completing projects across multiple CROs and pharmaceutical companies worldwide. Rest assured, your trial is in expert hands

Strategic Partnership

Long-term partnerships with our clients are central to our business. We view ourselves as an extension of your company, providing expert guidance, quick turnaround, and reliable deliverables.

Tailored Solution

Our size and culture make us an ideal partner for startups and newly established pharmaceutical or biotech companies. As a nimble team, we initiate projects promptly and iterate swiftly to provide cost-effective clinical trial services.

Local Sponsorship

We assist international companies conducting clinical trials in Australia by facilitating local sponsor representatives, enabling your company to benefit from the government's tax rebate of up to 43.5%.

Industry Best Practices

Our team are clinical operation experts, guiding your research from feasibility to closeout.

Plan

Our expert team provides strategic direction and tailored advice for every step of your clinical trial planning.

Execute

Our dedicated Project Manager ensures timely execution of your study , tracking progress and consistently providing feedback to the sponsor.

Review

We'll  routinely review, share, and discuss your study's progress and milestones to ensure quality, timeliness, and budget adherence.

The Australian Advantage

We will assist you in leveraging Australia's clinical ecosystem to execute your clinical trial program to its fullest potential.

Efficient Regulatory Processes  
Internationally Recognised Standards
Lowered drug development expenses